Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction (Scientific Reports, (2020), 10, 1, (16596), 10.1038/s41598-020-73593-0)

Ahmed Al‑Darraji, Renée R. Donahue, Himi Tripathi, Hsuan Peng, Bryana M. Levitan, Lakshman Chelvarajan, Dalia Haydar, Erhe Gao, David Henson, John C. Gensel, David J. Feola, Vincent J. Venditto, Ahmed Abdel‑Latif

Research output: Contribution to journalComment/debate

Abstract

The Acknowledgements section in this Article is incomplete. “The UK Flow Cytometry & Cell Sorting core facility is supported in part by the Office of the Vice President for Research, the Markey Cancer Center and an NCI Center Core Support Grant (P30 CA177558) to the University of Kentucky Markey Cancer Center.” should read: “The UK Flow Cytometry & Cell Sorting core facility is supported in part by the Office of the Vice President for Research, the Markey Cancer Center and an NCI Center Core Support Grant (P30 CA177558) to the University of Kentucky Markey Cancer Center. V.J.V. was supported by the University of Kentucky Center for Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation (CPRI, NIH P20GM130456) and a grant from the National Institutes of Health (R01HL152081).”.

Original languageEnglish
Article number6654
JournalScientific Reports
Volume11
Issue number1
DOIs
StatePublished - Dec 2021

Bibliographical note

Publisher Copyright:
© 2021, The Author(s).

Funding

“The UK Flow Cytometry & Cell Sorting core facility is supported in part by the Office of the Vice President for Research, the Markey Cancer Center and an NCI Center Core Support Grant (P30 CA177558) to the University of Kentucky Markey Cancer Center.” “The UK Flow Cytometry & Cell Sorting core facility is supported in part by the Office of the Vice President for Research, the Markey Cancer Center and an NCI Center Core Support Grant (P30 CA177558) to the University of Kentucky Markey Cancer Center. V.J.V. was supported by the University of Kentucky Center for Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation (CPRI, NIH P20GM130456) and a grant from the National Institutes of Health (R01HL152081).” Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

FundersFunder number
University of Kentucky Markey Cancer Center
University of Kentucky Markey Cancer Center
National Childhood Cancer Registry – National Cancer InstituteP30 CA177558
Office of the Vice President for Research
University of Kentucky Markey Cancer Center
University of Kentucky Center for Biomedical Research Excellence
University of Kentucky Markey Cancer Center
Corporacion Nacional del Cobre
National Institutes of Health (NIH)R01HL152081
National Institutes of Health (NIH)P20GM130456
National Childhood Cancer Registry – National Cancer InstituteP30 CA177558
Office of the Vice President for Research

    ASJC Scopus subject areas

    • General

    Fingerprint

    Dive into the research topics of 'Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction (Scientific Reports, (2020), 10, 1, (16596), 10.1038/s41598-020-73593-0)'. Together they form a unique fingerprint.

    Cite this